Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPKO Health : Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

07/12/2021 | 08:01am EDT

MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA. AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein. CAMP4 has prioritized OPKO’s lead AntagoNAT compound to progress into clinical trials for the treatment of Dravet syndrome.

Under the terms of the agreement, OPKO will receive an upfront payment and shares of CAMP4. In addition, OPKO will be eligible to receive up to $93.5 million and additional shares upon the achievement of certain development and sales milestones for products developed from this technology and associated intellectual property. CAMP4 will also pay OPKO double-digit royalties on product sales.

“We are delighted to enter into this licensing agreement to accelerate the development and commercialization of potential disease-modifying therapeutics. With a clear focus on therapeutics that restore healthy gene expression, CAMP4 has the expertise to advance our Dravet syndrome compound through the necessary patient trials. This agreement validates our technology and allows OPKO to focus resources on other areas of our business. We continue to seek license opportunities to monetize and leverage our early-stage assets,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

According to the Epilepsy Foundation, Dravet syndrome is a rare, drug-resistant epilepsy that begins in the first year of life in an otherwise healthy infant. It is estimated that 1-in-20,000 to 1-in-40,000 individuals have Dravet syndrome. Most cases are due to SCN1A gene mutations and most children develop varying degrees of neurodevelopmental disability.  

CAMP4 is pioneering a novel approach to programmable therapeutics that combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. The company’s RNA Actuating Platform’s proprietary insights enable drug discovery and development that aims to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding product development efforts as well as other non-historical statements about our expectations, products, beliefs or intentions regarding our business, financial condition, strategies or prospects including statements regarding expectations about the success of the collaboration and licensing agreement with CAMP4, whether CAMP4 will successfully develop, obtain regulatory approval for, launch or commercialize any product using Dravet or non-Dravet technology that is part of the CURNA platform, whether payment milestones and royalty obligations will ever be triggered, and the expected market for the licensed products. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


LHA Investor Relations
Yvonne Briggs, 310-691-7100
Bruce Voss, 310-691-7100

Primary Logo

Source: OPKO Health, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about OPKO HEALTH, INC.
07:44aPFIZER : And opko announce extension of u.s. fda review of biologics license application o..
09/24PFIZER : OPKO Health Get FDA Extension for Review of Somatrogon Biologics License Applicat..
09/24Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application ..
09/14OPKO HEALTH : LeaderMed Form Joint Venture to Commercialize Two Drugs in Asia
09/14OPKO HEALTH : LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercial..
09/14Leadermed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntom..
09/13OPKO HEALTH : Another Diversity Suit Stifled
09/03OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
08/30OPKO HEALTH : Completes Phase 2 COVID-19 Study Enrollment at 171 Subjects
08/30OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment fo..
More news
Analyst Recommendations on OPKO HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 1 576 M - -
Net income 2021 -12,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -188x
Yield 2021 -
Capitalization 2 554 M 2 554 M -
Capi. / Sales 2021 1,62x
Capi. / Sales 2022 2,15x
Nbr of Employees 5 269
Free-Float 59,5%
Duration : Period :
OPKO Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPKO HEALTH, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,75 $
Average target price 6,60 $
Spread / Average Target 76,0%
EPS Revisions
Managers and Directors
Phillip Frost Chairman & Chief Executive Officer
Jon Roger Cohen Director & Senior Vice President
Adam E. Logal CFO, Treasurer, Chief Accounting Officer & SVP
Jane H. Hsaio Vice Chairman & Chief Technical Officer
Steven D. Rubin Director & Executive Vice President-Administration
Sector and Competitors
1st jan.Capi. (M$)
OPKO HEALTH, INC.-5.06%2 554
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485